Spark Therapeutics Stock
Your prediction
Pros and Cons of Spark Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Spark Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Spark Therapeutics | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | -3.820% | -0.781% | -9.286% | 117.094% | 53.012% | 319.835% | 171.194% |
| United Therapeutics | -0.580% | 3.809% | -5.572% | 81.464% | 9.057% | 115.541% | 156.044% |
| Ionis Pharmaceuticals Inc. | 1.990% | 8.773% | -35.384% | 39.931% | -28.119% | 37.451% | 47.985% |
News
Envista Q2 Earnings Call Highlights
Key Points
- Interested in Envista Holdings Corporation? Here are five stocks we like better.
- Strong second-quarter performance: Envista reported $731 million in sales, up just over 7% year over
Omada Health Q2 Earnings Call Highlights
Omada Health (NASDAQ:OMDA) reported record second-quarter results for 2026, citing broad-based growth across its cardiometabolic programs, expanding channel partnerships and lower costs to serve
Cirrus Logic Q1 Earnings Call Highlights
Key Points
- Interested in Cirrus Logic, Inc.? Here are five stocks we like better.
- Record quarterly performance: Cirrus Logic reported fiscal Q1 revenue of $460 million, up 13% year over year